Page last updated: 2024-08-24

1-(2',5'-bis-o-(tert-butyldimethylsilylribofuranosyl)-3-n-methylthymine)-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide) and Hepatitis C

1-(2',5'-bis-o-(tert-butyldimethylsilylribofuranosyl)-3-n-methylthymine)-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide) has been researched along with Hepatitis C in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Balzarini, J; Castelain, S; Duverlie, G; Fournier, C; Josse, S; Marco-Contelles, J; Moura, M; Nguyen Van Nhien, A; Postel, D; Soriano, E1

Other Studies

1 other study(ies) available for 1-(2',5'-bis-o-(tert-butyldimethylsilylribofuranosyl)-3-n-methylthymine)-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide) and Hepatitis C

ArticleYear
Synthesis and in vitro activity of novel N-3 acylated TSAO-T compounds against HIV-1 and HCV.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:10

    Topics: Cell Line; Chemistry Techniques, Synthetic; Hepacivirus; Hepatitis C; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Reverse Transcriptase Inhibitors; Small Molecule Libraries; Spiro Compounds; Thymidine; Uridine

2011